Medytox Selected for National New Drug Development Project for Myasthenia Gravis Treatment

'MT122', Autoimmune Disease Antibody Therapy
Accelerates New Drug Development... Speeds Up Candidate Substance Discovery

Medytox announced on the 6th that its myasthenia gravis treatment development project 'MT122' has been selected as a '2023 3rd National New Drug Development Project' led by the Korea Drug Development Fund (KDDF).

Exterior view of Medytox Seoul Office. [Photo by Medytox]

The National New Drug Development Project is a government-wide research and development (R&D) initiative that supports the entire drug development cycle, including candidate discovery, preclinical, and clinical trials, to strengthen the global competitiveness of the domestic pharmaceutical and bio industries. Medytox was selected for the 'New Drug R&D Ecosystem Establishment Research' project, which assists in deriving excellent candidate substances and entering clinical trials, and will receive research and development funding for candidate discovery over the next two years.

MT122 is an antibody therapeutic pipeline that Medytox is developing to treat myasthenia gravis, a rare autoimmune disease. Unlike existing treatments, it is characterized by the absence of immunosuppressive effects, which is expected to allow application to a broader range of patients. Additionally, Medytox explained that the drug requires a low dosage and is easy for patients to self-administer, enhancing its convenience of use.

A Medytox representative stated, "We will accelerate new drug development following the selection of MT122 for the National New Drug Development Project." They added, "Through the development of new pipelines that consolidate R&D capabilities and know-how, including the rare disease treatment 'MT107' and anticancer agents 'MT117,' 'MT124,' and 'MT133,' which are currently undergoing preclinical trials, as well as the next-generation lipolysis injection 'MT921,' which is preparing for domestic product approval application, we aim to become a global biopharmaceutical company."

Meanwhile, Medytox is also focusing its R&D capabilities on its core business area of botulinum toxin. With the goal of entering advanced global markets, it is accelerating the application for U.S. Food and Drug Administration (FDA) approval (BLA) of the non-animal liquid toxin formulation 'MT10109L.'